<DOC>
	<DOCNO>NCT01261754</DOCNO>
	<brief_summary>This single-blind , randomize , cross-over design . Patients metastatic prostate adenocarcinoma ; newly diagnose , high-risk patient prostate adenocarcinoma ; healthy subject administer single intravenous dose study drug 99mTc MIP 1404 99mTc MIP 1405 administer approximately 14 21 day apart .</brief_summary>
	<brief_title>A Study 99mTc-MIP-1404 99mTc-MIP-1405 Patients With Metastatic Prostate Adenocarcinoma Healthy Volunteers</brief_title>
	<detailed_description>This trial single-blind , randomize , cross-over design . Up six patient confirm metastatic prostate adenocarcinoma ; six newly diagnose , high-risk patient prostate adenocarcinoma ; six healthy volunteer receive 20.0 ( ± 3 ) mCi intravenously administer 99mTc MIP 1404 99mTc MIP 1405 . Whole-body planar scintigraphic image acquire various time post-injection 24 hour . A pelvic SPECT/CT image acquire first day . Blood urine collect pharmacokinetic measurement metabolic analysis 24 hour . Each patient receive initial study drug administration second study drug administration approximately 14 21 day first . A final follow-up visit occur approximately 2-3 week second study drug .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Participants must meet follow criterion enrol study . 1 . Male age 21 year old . 2 . Ability provide sign informed consent willingness comply protocol requirement . 3 . Participants must agree use condom period seven day injection , engage sexual activity . Additional Inclusion Criteria Patients : i. Histologic diagnosis prostate cancer validate medical history . ( Pathology report , available ) . ii . Evidence metastatic disease demonstrate documented abnormal bone scan , CT scan , MRI plus Clinical Stage 3 Gleason Score ≥ 8. iii . Karnofsky performance ≥ 60 . Additional Inclusion Criteria Healthy Volunteers : i. PSA laboratory assessment within normal range ( PSA &lt; 4 ng/ml ) . ii . Normal finding digital rectal examination . iii . Hemoglobin hematocrit within normal range . Participants must NOT meet follow criterion enrol study . 1 . Received investigational compound and/or medical device part investigational study within past 30 day enrollment study . 2 . Subject administer radioisotope within 5 physical half live radioisotope prior study enrollment 3 . Have medical condition circumstance , opinion Investigator , would significantly decrease chance obtain reliable data , achieve study objective , complete study and/or post dose followup examination . 4 . Participant determine Investigator clinically unsuitable study . 5 . Serum creatinine ≥ 2.0 mg/dl 6 . Total bilirubin ≥ 2.0 mg/dl 7 . Liver transaminases ≥ 1.5 x ULN 8 . Platelet count &lt; 150,000/mm3 9 . Absolute neutrophil count ( ANC ) &lt; 2,000/mm3 . 10 . Hematocrit &lt; 30 % hemoglobin &lt; 10 g/dl . 11 . Abnormal coagulation profile ( PT , PTT INR ) &gt; 1.3 ULN unless therapeutic anticoagulation . Additional Exclusion Criteria Patients : Patients exclude study follow criterion observe : i. Androgen deprivation therapy form hormonal therapy stable period 14 day prior screen . ii . Subject receive permanent prostate brachytherapy implant within last 3 month 103Pd implant ; 12 month 125I implant . iii . Subject expect start cytotoxic chemotherapy study period . iv . Has malignancy within past year , basal squamous cell carcinoma skin , diagnosis location must define define clinically control treat complete response . Additional Exclusion Criteria Healthy Volunteers : Healthy Volunteers exclude study follow criterion observe : . Have malignancy within 5 year basal squamous cell carcinoma skin . ii . History known prostate adenocarcinoma , prostate surgery/biopsy , prostatitis and/or symptom suggestive associate possible prostatitis within 6 month enrollment .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Metastatic Prostate Adenocarcinoma</keyword>
</DOC>